Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Treatment for spasticity after stroke

https://doi.org/10.14412/2074-2711-2010-106

Full Text:

Abstract

The epidemiology, symptomatology, pathogenesis, diagnosis of post-stroke spasticity, and its basic treatment principles based on the current methods of evidence-based medicine are described. Possibilities for post-stroke spasticity therapy with botulinum, in particular botulinum
toxin type A (Xeomin) used in these patients, are discussed.

References

1. <div><p>Проект WHO MONICA, Stegmayr, 1997; www.wemove.org/spa</p><p>Bakheit M. Botulinum toxin treatment of muscle spasticity. 2nd ed. AuthorHouse, 2007;216 p.</p><p>Dietz V. Spastic movement disorder (Review). Spinal Cord 2000;38:389-93.</p><p>Upper motor neuron syndrome and spasticity: clinical management and neurophysiology (Cambridge Medicine). 2nd ed. Cambridge University Press, 2008;264 p.</p><p>Ward A.B. Handbook of the management of adult spasticity course. Stoke on Trent, 2008.</p><p>Rosales R.L., Chua-Yap A.S. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transmits 2008;115(4):617-23.</p><p>Simpson D.M., Gracies J.-M., Graham H.K. et al. Assessment: Botulinum toxin for the treatment of spasticity (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008 May 6;70(19):1691-8.</p><p>Spasticity in adults: Management using botulinum toxin. National Guidelines. Royal College of Physicians, 2009.</p><p>Therapie der spastischen Syndroms. In: Leitlinien fuer Diagnostik und Therapie in der Neurologie. 4 ueberarbeitete Auflage. Stuttgart: Georg Thieme Verlag, 2008;S.654 ff.</p><p>Wissel J., Ward A.B., Erztgaard P. et al. European consensus table on the use of botu-linum toxin type A in adult spasticity. J Rehabil Med 2009;41:13-25.</p><p>Barnes M., Schnitzler A., Amaral e Silva A. et al. NT 201 (Xeomin®; botulinum neurotoxin free from complexing proteins) is efficacious and well-tolerated in upper limb spasticity of various etiologies. Abstracts of the Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders, Paris 2009, 7-11 June. Mov Disord 2009;24(Suppl. 1):S450.</p><p>Barnes M., Schnitzler A., Medeiros L. et al. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies - a randomized parallel-group study. Acta Neurol Scand: DOL: 10.1111. j.1600-0404.2010.01354.x. © 2010 The Authors Journal compilation © 2010 Blackwell Munksgaard.</p><p>Kanovsky P. et al. Mov Disord 2009;24(Suppl. 1):S450.</p><p>Kanovsky P. et al. Poster presented at WCNR, Brasilia, 2008.</p><p>Kanovsky P., Slawek J., Denes Z. et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacology 2009 Sept-Oct;32(5):259-65.</p><p>Dressler D., Mander G.J., Fink K. Equivalent potency of Xeomin® and Botox®. Mov Disord 2008;23(Suppl. 1):S20-1.</p></div><br />


For citation:


Khatkova S.E. Treatment for spasticity after stroke. Neurology, Neuropsychiatry, Psychosomatics. 2010;2(3):76-80. (In Russ.) https://doi.org/10.14412/2074-2711-2010-106

Views: 383


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)